India, Oct. 26 -- TransCode Therapeutics, Inc. (RNAZ) presented Phase 1a clinical data for TTX-MC138, an investigational RNA-based therapy targeting metastatic cancers, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
The ongoing study evaluated the safety, tolerability, pharmacokinetics and preliminary antitumor activity of TTX-MC138 in patients with previously treated advanced solid tumors.
TTX-MC138 was administered once every 28 days across four evaluated dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.
The study met its primary safety endpoint, with no dose-limiting toxicities observed.
Plasma drug exposure increased in a dose-dependent manner across the evaluated dose levels.
googletag.cmd.push(...